Bristol-Myers Squibb Compnay

Bristol-Myers Squibb Pharma Company

E.i. Dupont De Nemours and Company

The Dupont Merck Pharmaceutical Company

Other

Dupont Pharmaceuticals Company

Bristol-Myers Squibb

Dupont Pharmaceuticals, Inc.

Ruth Richmond Wexler

Donald J P Pinto

Irina C Jacobson

Mimi Lifen Quan

William R Ewing

James R Corte

Wu Yang

Michael J Orwat

Leon M Smith, Ii

Yufeng Wang

Tianan Fang

Yeheng Zhu

Andrew K Dilger

Kumar Balashanmuga Pabbisetty

Indawati De Lucca

C Anne Higley

Qi Han

Patrick Y S Lam

Richard Gerald Wilde

Jeffrey T Billheimer

Thomas P Maduskuie, Jr

John Matthew Fevig

Carl P Decicco

Joanne M Smallheer

Karen Anita Rossi

Robert A Galemmo, Jr

Charles G Clark

James Russell Pruitt

Celia Dominguez

Peter John Gillies

Shuaige Wang

Renhau Li

Jeongsook Maria Park

Daniel Emmett Duffy

Petrus B Timmermans

Donald Jp Pinto

Albert Jean Robichaud

Yun-Long Li

Chu-Biao Xue

Jennifer X Qiao

Taekyu Lee

Robert J Ardecky

John J Duncia

Matthew Ernst Voss

David J Carini

Donald J Pinto

Wenting Chen

Wei Deng

Suanne Nakajima

Alexander L Johnson

Andrew T Chiu

Donald Joseph Phillip Pinto

Thomas P Muduskuie, Jr

Mimi Lifen Ouan

Philip Ma

Leon M Ii Smith

Leon M Smith Ii

Donald JP Pinto

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Pyrimidinones as factor XIA inhibitors

The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Pyrimidinones as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocyclic factor XIa inhibitors bearing heterocyclic groups

Macrocycles with aromatic P2' groups as factor xia inhibitors

The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HTreceptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists

The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I:or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors

The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Substituted amino methyl factor Xa inhibitors

This invention relates generally to a novel class of bicyclic heterocyclic compounds of the Formula (I):or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

Bicyclic inhibitors of factor Xa

Fused heterocyclic inhibitors of factor Xa

Aryl sulfonyls as factor Xa inhibitors

This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

Thrombin or factor Xa inhibitors

6-membered aromatics as factor Xa inhibitors

Growing community of inventors

Wilmington, DE, United States of America

Ruth Richmond Wexler